PanaMa: maintenance FU/FA with or without panitumumab in mCRC
Автор: VJOncology
Загружено: 2024-06-18
Просмотров: 123
Описание:
Dominik Paul Modest, MD, Charité – Universitätsmedizin Berlin, Berlin, Germany, discusses findings from the Phase II PanaMa trial (NCT01991873), which assessed folinic acid plus 5-fluorouracil (FU/FA) maintenance therapy with or without panitumumab in RAS wild-type metastatic colorectal cancer (mCRC). Progression-free survival (PFS), the primary endpoint, was significantly improved with the addition of panitumumab. However, long term benefits remain suboptimal. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
